EMLy Co-pilot

Enter EMLy Co-pilot, an AI-powered platform that unifies workflows and democratizes access to some of the most powerful machine learning tools in biologics design.

Emly is a conversational, agentic platform that truncates biologics discovery from weeks to minutes. Scientists can decode, predict, and design candidates through a simple chat interface, while EMLy orchestrates the heavy lifting by integrating models, datasets, and computational tools to deliver high-impact, design-ready outputs. Powered by state-of-the-art generative and agentic AI, it turns natural language into actionable science.

The multi-modal platform adapts to any therapeutic challenge, accelerating the design and optimization of T cell receptors, antibodies, bi-specifics and VHH fragments. Underpinned by a rich immunological dataset and experimental validation, EMLy enables drug development teams to start smarter and discover faster, lowering the barrier to scientific innovation.

The platform empowers teams to explore ideas that once required substantial time, cost, and specialist expertise. Its unique intelligence helps scientists de-risk early exploration, identify liabilities earlier in the process, and avoid costly downstream failures particularly around developability.

The unique, natural language-driven interface enables iterative thinking, design branching and exploratory reasoning to produce and evaluate variants in minutes. This enables the decision-making flow of scientists, where hypotheses evolve rapidly and benefit from immediate computational feedback.

The outcome is not just more options, but higher-quality, more developable lead candidates. Additionally, with multi-specifics handling, its easier than ever to engineer complex, multi-domain biologic molecules such as bi or trispecifics.

EMLy Co-pilot condenses time-consuming workflows into minutes of intuitive interactions. Designed to feel more like a scientifically fluent lab partner than a machine, the platform dramatically accelerates early biologics R&D, cutting timelines by more than half in many cases.

The launch of EMLy Co-pilot marks the beginning of a new era in immunotherapeutic design. Upcoming releases will unlock full repertoire analysis for rapid lead identification, and tools for bespoke antibody library design. Soon, EMLy will also offer in silico co-complex prediction, providing unprecedented insight into paratope-epitope interfaces and enabling routine affinity optimization.

By compressing years of protein engineering into minutes of guided interaction, Etcembly empowers scientists everywhere to start smarter, discover faster, and create more effective therapies at the speed of imagination.